← All stories
Markets
Amid Legal Risks, This Company Is Still Rated a Buy
PACS Group shares have rebounded after a Medicare billing scandal, with strong Q2 earnings and Buy ratings, though DOJ and SEC investigations and shareholder lawsuits remain unresolved.
Covered by 1 outlet
All coverage · 1 article